


1626

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0654-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)		<b>Application Number</b>	09/856,009
		<b>Filing Date</b>	May 16, 2001
		<b>First Named Inventor</b>	Kozak et al.
		<b>Group Art Unit</b>	2594
		<b>Examiner Name</b>	Sonya N. Wright
<b>Total Number of Pages in This Submission</b>	33	<b>Attorney Docket Number</b>	800.1012

RECEIVED  
MAR 07 2003  
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input checked="" type="checkbox"/> Amendment / Response  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - return receipt postcard
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
<b>Name</b>	Davidson, Davidson & Kappel, LLC				
<b>Address</b>	485 Seventh Avenue, 14 <sup>th</sup> Floor				
<b>City</b>	New York	<b>State</b>	NY	<b>Zip Code</b>	10018
<b>Country</b>	USA	<b>Telephone</b>	(212) 736-1940	<b>Fax</b>	(212) 736-2427
<b>Individual name</b>	Morey B. Wildes				
<b>Signature</b>					
<b>Date</b>	February 26, 2003				

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: February 26, 2003			
<b>Typed or printed name</b>	Morey B. Wildes		
<b>Signature</b>		<b>Date</b>	February 26, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: KOZAK, et al.

Serial No.: 09/856,009

Filed: May 16, 2001

For: **PHOSPHOLIPID DERIVATIVES OF  
NON-STEROIDAL ANTI-  
INFLAMMATORY DRUGS**

Examiner: Sonya N. Wright (Group Art Unit: 1626)

**RECEIVED**

MAR 07 2003

TECH CENTER 1600/2900

Box: NON-FEE AMENDMENT  
Commissioner for Patents  
Washington, D.C. 20231

February 26, 2003

**SUPPLEMENTAL PRELIMINARY AMENDMENT**

S I R:

Preliminary to examination, please amend the above-identification as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 2, line 29 with the following rewritten paragraph:

a1  
Diclofenac ([o-[(2,6-dichlorophenyl)amino]phenyl]acetate) is a non-steroidal anti-inflammatory drug of the phenylacetic acid class. When given orally the absorption of diclofenac is rapid and complete. It binds extensively to plasma albumin. Substantial concentrations of drug are attained in synovial fluid, which is the proposed site of action of the NSAIDs. Diclofenac is a potent inhibitor of prostaglandin synthesis and has also been shown to inhibit interleukin-1 (IL-1 $\beta$ ) and tumor necrosis factor alpha (TNF- $\alpha$ ), involved in osteoarthritis. Gastrointestinal complications such as ulceration and intolerance are the most common adverse effect of diclofenac. Renal dysfunction and hypersensitivity reactions also occur. Many patients with